Analytical Data
-
Gene name
GRO-alpha/CXCL1
-
简介
CXCL1 (Chemokine (C-X-C motif) ligand 1), also known as GRO alpha, NAP-3 or MGSA, belongs to the sub-family of CXC chemokine. CXCL1 is involved in the development of many inflammatory diseases, including the induction of angiogenesis and recruitment of neutrophils. CXCL1 is produced by many cell types, and activates CXCR2 and, at high levels, CXCR1[1]. GRO-alpha/CXCL1 Protein, Human (HEK293, His) is produced in HEK293 cells with a C-Terminal His-tag. It consists of 73 amino acids (A35-N107).
- Application
-
Biological Activity
1.Measured in a cell proliferation assay using HUVEC cells.The ED50 for this effect is 3.689 ng/mL, corresponding to a specific activity is 2.71×105U/mg. 2.Determined by its ability to chemoattract BaF3 mouse pro-B cells transfected with human CXCR2. The ED50 for this effect is 3.516 ng/mL, corresponding to a specific activity is 2.84×105 U/mg. Measured in a cell proliferation assay using HUVEC cells.The ED50 for this effect is 3.689 ng/mL, corresponding to a specific activity is 2.71×105 U/mg.
-
Alternative Names
Growth-Regulated Alpha Protein; C-X-C Motif Chemokine 1; GRO-Alpha(1-73); Melanoma Growth Stimulatory Activity; MGSA; Neutrophil-Activating Protein 3; NAP-3; CXCL1; GRO; GRO1; GROA; MGSA; SCYB1
-
Species
Human
-
Source
HEK293
-
Tag
C-6*His
-
Purity
Greater than 95% as determined by reducing SDS-PAGE.
-
Uniprot
P09341
-
Expression Region
A35-N107
-
Protein Length
Full Length of Mature Protein
-
Molecular Weight
9-14 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Related Products
Protein Description
GRO-alpha, also known as CXCL1, is a CXC chemokine involved in the inflammatory response and plays a crucial role in the recruitment of neutrophils to sites of injury or infection. Research on GRO-alpha/CXCL1 has gained significant attention due to its involvement in various physiological and pathological processes, including cancer progression, wound healing, and immune responses. Elevated levels of GRO-alpha have been associated with tumor growth, angiogenesis, and metastasis, making it a potential biomarker for various cancers. Additionally, GRO-alpha is implicated in chronic inflammatory diseases, such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD), highlighting its relevance in understanding inflammation-induced tissue damage. The study of recombinant GRO-alpha protein has advanced our knowledge of its structure-function relationships and allowed for the exploration of its therapeutic applications, such as targeted cancer therapies and anti-inflammatory treatments. By utilizing recombinant technology, researchers can produce GRO-alpha in a controlled manner, facilitating the investigation of its biological activities and the development of inhibitors that modulate its function in pathological conditions. Overall, the comprehensive understanding of GRO-alpha/CXCL1's role in both health and disease underscores the importance of ongoing research in this area, paving the way for novel therapeutic strategies.
